Bio-Rad Laboratories (BIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2018 | 12-2017 | 12-2016 | 12-2015 | 12-2014 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 431,526 | 383,824 | 456,264 | 457,549 | 413,251 |
| Marketable Securities | 418,830 | 376,714 | 387,736 | 332,928 | 284,384 |
| Receivables | 392,443 | 464,847 | 372,348 | 391,485 | 377,640 |
| Inventories | 583,815 | 594,804 | 524,961 | 490,224 | 470,997 |
| Other current assets | 9,615 | 10,325 | 12,201 | 11,041 | 61,747 |
| TOTAL | $2,023,478 | $1,976,649 | $1,844,524 | $1,777,596 | $1,716,367 |
| Non-Current Assets | |||||
| PPE Net | 508,690 | 493,496 | 488,614 | 437,690 | 428,836 |
| Investments And Advances | 2,655,709 | 1,027,736 | 830,790 | 719,840 | 389,309 |
| Intangibles | 352,893 | 680,182 | 638,724 | 709,974 | 754,669 |
| Other Non-Current Assets | 70,298 | 94,949 | 47,852 | 64,618 | 52,097 |
| TOTAL | $3,587,590 | $2,296,363 | $2,005,980 | $1,932,122 | $1,624,911 |
| Total Assets | $5,611,068 | $4,273,012 | $3,850,504 | $3,709,718 | $3,341,278 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 493 | 420 | N/A | N/A | 265 |
| Accounts payable and accrued liabilities | 122,450 | 135,182 | 133,109 | 122,391 | 128,608 |
| Accrued Expenses | 143,510 | 171,632 | 163,364 | 157,857 | 153,426 |
| Other current liabilities | 101,218 | 127,288 | 115,388 | 101,783 | 102,581 |
| TOTAL | $450,795 | $502,696 | $471,322 | $441,351 | $446,761 |
| Non-Current Liabilities | |||||
| Long Term Debt | 438,937 | 434,581 | 434,186 | 433,883 | 435,710 |
| Deferred Revenues | 26,936 | 28,233 | 31,003 | 29,683 | 26,716 |
| aiOther Non-Current Liabilities | 147,766 | 183,276 | 140,537 | 110,506 | 118,735 |
| TOTAL | $1,139,942 | $840,066 | $800,022 | $777,864 | $709,362 |
| Total Liabilities | $1,590,737 | $1,342,762 | $1,271,344 | $1,219,215 | $1,156,123 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 29,800 | 29,805 | 29,577 | 29,362 | 29,102 |
| Common Shares | 3 | 3 | 3 | 3 | 3 |
| Retained earnings | 3,722,073 | 1,830,439 | 1,828,581 | 1,808,055 | 1,694,962 |
| Other shareholders' equity | -47,087 | 738,577 | 417,665 | 382,037 | 218,844 |
| TOTAL | $4,020,331 | $2,930,250 | $2,579,160 | $2,490,503 | $2,185,155 |
| Total Liabilities And Equity | $5,611,068 | $4,273,012 | $3,850,504 | $3,709,718 | $3,341,278 |